Sign Out
Click on icon to see table/diagram/imageDrugs Having No Clinically Important Interactions with REXULTI: Based on pharmacokinetic studies, no dosage adjustment of REXULTI is required when administered concomitantly with CYP2B6 inhibitors (e.g., ticlopidine) or gastric pH modifiers (e.g., omeprazole). Additionally, no dosage adjustment for substrates of CYP2D6 (e.g., dextromethorphan), CYP3A4 (e.g., lovastatin), CYP2B6 (e.g., bupropion), BCRP (e.g., rosuvastatin), or P-gp (e.g., fexofenadine) is required when administered concomitantly with REXULTI.
As with other antipsychotics, caution should be used if REXULTI is administered concomitantly with medicinal products known to cause QT prolongation or electrolyte imbalance.
Food: Intake of food has no effect on the pharmacokinetics of REXULTI.
